ReMission Foundation Selects its 2026 Recipient

For 2026, ReMission Foundation is pleased to support Darren Feldman, MD, Section Head for Germ Cell Tumors (GCTs) within the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), and his innovative research treating testicular cancer.

GCTs are responsible for over 95% of cases of testicular cancer and are the most common cancers diagnosed in men ages 15 to 40. GCTs occasionally arise in areas around the thoracic or abdominal cavities, even if there is no evidence of cancer in or near the testicle. When GCTs advance following salvage treatment, they are considered incurable because of inadequate treatment options. In an analysis of 90 patients with relapsed/refractory GCTs treated at MSK, the average survival time was just four months. These people are young and in the prime of their lives, magnifying the devastation when a patient succumbs to the disease. A death from GCT results in the greatest number of average life years lost from any adult malignancy. New and improved therapies are urgently needed to change the treatment paradigm for patients with relapsed/refractory GCTs.

To learn more about Dr. Feldman's efforts to battle GCT cancers, please visit our Annual Cause page here.